So, you want to get better at those tricky LeetCode Python problems, huh? It’s a common goal, especially if you’re aiming for tech jobs. Many people try to just grind through tons of problems, but ...

JetBrains, the company behind the popular PyCharm IDE, offers a free introductory Python course. This is a pretty neat option if you like learning by doing, especially within a professional coding ...

The Contagious Interview campaign weaponizes job recruitment to target developers. Threat actors pose as recruiters from crypto and AI companies and deliver backdoors such as OtterCookie and ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock tumbled 12% Wednesday morning after regulatory filings revealed that NVIDIA (NASDAQ:NVDA) had completely divested its stake in the ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

The funding discussions highlight ongoing investor demand for new and unproven research labs looking to find novel approaches to AI that push the technology forward. Recursive’s goal is to develop ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Andres Almiray, a serial open-source ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...